Drug Trial Radar · NCT04628026
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
650
Planned (sponsor's estimate)
Start
Sep 13, 2022
Primary completion
Mar 2029
Study completion Feb 2032
Sponsor
- Lead sponsor
- University of UlmAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- First posted
- Nov 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Placebo-Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2
Conditions
- Acute Myeloid Leukemia
Interventions
VenetoclaxDrug
Venetoclax will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
PlaceboDrug
Placebo will be administered in Induction cycle 1, Induction cycle 2 and in the chemo consolidation therapy in addition to the standard chemotherapy
Standard chemotherapyCombination product
Induction cycle 1: Patients will receive cytarabine 200 mg/m2 continuous IV (days 1-7) and daunorubicin 60 mg/m2 IV (days 1-3). Induction cycle 2: Patients ≤ 60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4, and daunorubicin 60 mg/m2 IV (days 1-3). Patients \>60 yrs will receive cytarabine 1000 mg/m2 BID (3h IV), days 1-4 without daunorubicin. Consolidation chemotherapy with intermediate doses of cytarabine. Patients ≤60 yrs will receive up to 3 cycles of IDAC (single dose 1500 mg/m2 every 12 hours, days 1-3). Patients who are \>60 yrs will receive up to 3 cycles of IDAC with single doses of 1000 mg/m2, every 12 hours, days 1-3. In patients \>60 yrs less than 3 cycles of IDAC or dose-reduced IDAC (500 mg/m2 per single dose) may be given based on an individual risk assessment.
Allogeneic stem cell transplantationOther
Generally, patients will proceed to allogeneic HCT upon completion of remission induction chemotherapy. It is however allowed, as per investigator's discretion, for a patient to receive 'bridging' consolidation chemotherapy in exceptional cases of delay towards transplantation. At baseline, HLA-compatible donor search must be initiated as soon as possible, first among siblings and second in the world donor bank for unrelated donors or cord blood. In order to avoid inappropriate delay in cases where no suitable sibling is present, high-resolution HLA typing should be performed immediately after registration, enabling a more rapid matched-unrelated donor search. In case no sibling or unrelated donor can be identified, haploidentical allogeneic HCT is allowed. Conditioning and GVHD prophylaxis will take place according to institutional guidelines. Patients who undergo allogeneic HCT will not receive venetoclax during conditioning, engraftment or after hematologic recovery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event Free Survival (EFS)Time frame: 6 months/16 months after inclusion of last patient
- Frequency of dose-limiting toxicities (DLTs) during the observation period (Primary safety endpoint during dose-finding phase)Time frame: after cycle 1 (maximal day 42)
Locations
91 sites in 8 countries. Site status is shown where the registry gives one.
Tirol Kliniken GmbH
Innsbruck, Austria · Not yet recruiting
Kepler Universitaetsklinikum GmbH
Linz, Austria · Not yet recruiting
Ordensklinikum Linz GmbH
Linz, Austria · Recruiting
Landeskrankenhaus (LKH) Rankweil, Interne E am Landeskrankenhaus Rankweil
Rankweil, Austria · Recruiting
Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH
Salzburg, Austria · Not yet recruiting
Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
Vienna, Austria · Recruiting
Ziekenhuis Aan De Stroom
Antwerp, Belgium · Not yet recruiting
Az St-Jan Brugge-Oostende A.V.
Bruges, Belgium · Recruiting
Universitair Ziekenhuis Brussel
Brussels, Belgium · Recruiting
Katholieke Universiteit te Leuven
Leuven, Belgium · Not yet recruiting
Algemeen Ziekenhuis Delta
Roeselare, Belgium · Recruiting
CHU UCL NAMUR - Mont Godinne
Yvoir, Belgium · Recruiting
North Estonia Medical Centre Foundation
Tallinn, Estonia · Recruiting
Tartu University Hospital
Tartu, Estonia · Recruiting
Helsinki University Central Hospital Meilahden Kolmiosairaala
Helsinki, Finland · Recruiting
Tampere University Hospital
Tampere, Finland · Not yet recruiting
Klinikum Aschaffenburg-Alzenau gGmbH
Aschaffenburg, Germany · Recruiting
HELIOS Klinikum Bad Saarow GmbH
Bad Saarow, Germany · Recruiting
Charité Berlin - Campus Mitte
Berlin, Germany · Recruiting
Charité Berlin - Campus Benjamin Franklin
Berlin, Germany · Recruiting
Charité Berlin - Campus Virchow Klinikum
Berlin, Germany · Recruiting
Vivantes am Urban
Berlin, Germany · Not yet recruiting
Vivantes Neukölln
Berlin, Germany · Not yet recruiting
Vivantes Spandau
Berlin, Germany · Withdrawn
Knappschaftskrankenhaus Bochum-Langendreer
Bochum, Germany · Recruiting
Uniklinikum Bonn
Bonn, Germany · Recruiting
Staedtisches Klinikum Braunschweig
Braunschweig, Germany · Recruiting
Gesundheit Nord gGmbH Klinikverbund Bremen
Bremen, Germany · Recruiting
Klinikum Darmstadt GmbH
Darmstadt, Germany · Recruiting
St. Johannes Hospital Dortmund
Dortmund, Germany · Recruiting
Marien Hospital Duesseldorf GmbH
Düsseldorf, Germany · Withdrawn
Klinikum Frankfurt Hoechst GmbH
Frankfurt, Germany · Recruiting
Justus-Liebig-Universitaet Giessen
Giessen, Germany · Recruiting
Wilhelm-Anton-Hospital Goch
Goch, Germany · Recruiting
Universitätsmedizin Greifswald
Greifswald, Germany · Recruiting
Univeritätsklinikum
Halle, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany · Recruiting
Asklepios Klinik Altona
Hamburg, Germany · Recruiting
Asklepios Klinik St Georg
Hamburg, Germany · Recruiting
Medizinische Hochschule Hannover
Hanover, Germany · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.